Literature DB >> 7081275

Plasma lipid alterations in leukemia and lymphoma.

R J Spiegel, E J Schaefer, I T Magrath, B K Edwards.   

Abstract

Plasma lipids and lipoproteins were studied at presentations in 25 patients with acute leukemia and non-Hodgkin's lymphoma. All patients demonstrated an abnormally in at least one plasma lipid fraction, and most exhibited a predictable pattern of lipid alterations that consisted of extremely low levels of high-density lipoprotein cholesterol (median [Xm] = 23), elevated triglyceride (Xm = 165) and elevated very-low-density lipoprotein (Xm = 26). Patients restudied during remission demonstrated a return to normal values. The degree of lipid abnormality was directly related to the underlying tumor burden and particularly to the presence of bone marrow involvement. However, even patients with minimal tumor bulk demonstrated plasma lipid abnormalities. The results suggest that an abnormality in systemic lipid metabolism, possibly in triglyceride clearance, is present in these patients and that its incidence in this population is high.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7081275     DOI: 10.1016/0002-9343(82)90543-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  23 in total

1.  Novel compounds that target lipoprotein lipase and mediate growth arrest in acute lymphoblastic leukemia.

Authors:  Rajesh R Nair; Werner J Geldenhuys; Debbie Piktel; Prabodh Sadana; Laura F Gibson
Journal:  Bioorg Med Chem Lett       Date:  2018-03-23       Impact factor: 2.823

2.  Effects of recombinant monokines on hepatic pyruvate dehydrogenase, pyruvate dehydrogenase kinase, lipogenesis de novo and plasma triacylglycerols. Abolition by prior fasting.

Authors:  M Blackham; D Cesar; O J Park; T C Vary; K Wu; S Kaempfer; C H Shackleton; M K Hellerstein
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

3.  Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma.

Authors:  Liang Wang; Pei-dong Chi; Hao Chen; Jin Xiang; Zhong-jun Xia; Yu-jing Zhang
Journal:  Tumour Biol       Date:  2014-03

4.  Severe lactic acidosis, hypertriglyceridemia, and extensive axial skeleton involvement in a case of disseminated Burkitt's lymphoma.

Authors:  Ketan Kulkarni; Satvinder Kaur; Anupam Sibal; Nameet Jerath; Laxman S Arya
Journal:  Int J Hematol       Date:  2010-03-09       Impact factor: 2.490

Review 5.  Metabolic alteration in patients with cancer: nutritional implications.

Authors:  Y Sakurai; S Klein
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

6.  NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.

Authors:  J C Pickup; M B Mattock; G D Chusney; D Burt
Journal:  Diabetologia       Date:  1997-11       Impact factor: 10.122

7.  Isolation and characterization of an RNA-proteolipid complex associated with the malignant state in humans.

Authors:  A J Wieczorek; C Rhyner; L H Block
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

8.  Serum lipids and apolipoproteins in women with breast masses.

Authors:  D M Lane; K K Boatman; W J McConathy
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

9.  Increased serum concentrations of cholesterol and triglycerides in the progression of breast cancer.

Authors:  C C Zielinski; I Stuller; P Rausch; C Müller
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

10.  Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis.

Authors:  Sharon Hensley Alford; George Divine; Chun Chao; Laurel A Habel; Nalini Janakiraman; Yun Wang; Heather Spencer Feigelson; Delia Scholes; Doug Roblin; Mara M Epstein; Lawrence Engel; Suzanne Havstad; Karen Wells; Marianne Ulcickas Yood; Joan Fortuny; Christine Cole Johnson
Journal:  Cancer Causes Control       Date:  2017-11-30       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.